Evaluation of Serum Level of Carnitine in Children with Acute Pyelonephritis (APN) Compared to Healthy Children

Author(s): Golnaz Vaseghi, Azadeh Eshraghi*, Nahid Rahimzadeh, Hasan Amiri, Mohammadreza Jahed

Journal Name: Reviews on Recent Clinical Trials

Volume 16 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Aim: This cross-sectional case-control study evaluated the serum carnitine level in children with urinary tract infection (UTI).

Background: Acute pyelonephritis (APN) is a common bacterial infection of the upper urinary tract in children which may also lead to renal damage and tubular atrophy. Activation of inflammatory mediator bedside alterations in the cytokines and generation of reactive oxygen species (ROS) play a striking role in the development of tissue damage after pyelonephritis. L-carnitine as one of the most potent natural antioxidant agents by inhibition of lipid peroxidation may protect cells and tissues from damage.

Methods: A total of 30 children with UTI (as a case group) and 30 healthy children (as a control group) which matched in terms of age and sex were enrolled in this study. All children were evaluated and compared with respect to age, sex, weight, body mass index (BMI) and serum carnitine level. Serum carnitine level was determined using serum carnitine ELISA kit.

Results: Demographic and clinical data such as age, sex, weight and BMI were not statistically significant between the two groups. The serum carnitine levels were significantly lower in the case group with UTI than the control group. Mean serum carnitine concentration in the case group and in the control group was 36.56 ± 9.87 μmol/l and 62.8±21.35, respectively (P = 0.001).

Conclusion: According to our study, it could be concluded that low serum L-carnitine level is linked to UTI in children. Therefore, further studies are needed to confirm our results.

Keywords: Antioxidant, carnitine, carnitine serum level, children, infection, pyelonephritis.

[1]
Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH, Wald ER. Imaging studies after a first febrile urinary tract infection in young children. N Engl J Med 2003; 348(3): 195-202.[http://dx.doi.org/10.1056/NEJMoa021698] [PMID: 12529459]
[2]
Smith EA. Pyelonephritis, renal scarring, and reflux nephropathy: a pediatric urologist’s perspective. Pediatr Radiol 2008; 38(Suppl. 1): S76-82.[http://dx.doi.org/10.1007/s00247-007-0587-x] [PMID: 18071695]
[3]
Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012; 51(9): 553-72.[http://dx.doi.org/10.1007/BF03261931] [PMID: 22804748]
[4]
Angelini C, Trevisan C, Isaya G, Pegolo G, Vergani L. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clin Biochem 1987; 20(1): 1-7.[http://dx.doi.org/10.1016/S0009-9120(87)80090-5] [PMID: 3552320]
[5]
Ferreira GC, McKenna MC. L-Carnitine and acetyl-L-carnitine roles and neuroprotection in developing brain. Neurochem Res 2017; 42(6): 1661-75.[http://dx.doi.org/10.1007/s11064-017-2288-7] [PMID: 28508995]
[6]
Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002; 405(1): 55-64.[http://dx.doi.org/10.1016/S0003-9861(02)00342-9] [PMID: 12176057]
[7]
Rani PJ, Panneerselvam C. Effect of L-carnitine on brain lipid peroxidation and antioxidant enzymes in old rats. J Gerontol A Biol Sci Med Sci 2002; 57(4): B134-7.[http://dx.doi.org/10.1093/gerona/57.4.B134] [PMID: 11909877]
[8]
Sener G, Paskaloğlu K, Satiroglu H, Alican I, Kaçmaz A, Sakarcan A. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol 2004; 43(5): 698-705.[http://dx.doi.org/10.1097/00005344-200405000-00013] [PMID: 15071358]
[9]
Rebouche CJ. Carnitine.Modern Nutrition in Health and Disease (9th ed) NY, USA: Lippincott Williams and Wilkins pp 1992; 505-12.
[10]
Alesci S, Manoli I, Costello R, et al. Carnitine: The Science Behind a Conditionally Essential Nutrient.Annals of the New York Academy of Sciences NY, USA 2004; 1033
[11]
Apostolov N, Victor VM. Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications. Antioxid Redox Signal 2015; 22(8): 686-729.
[12]
Kolodziejczyk J, Saluk-Juszczak J, Wachowicz B. L-Carnitine protects plasma components against oxidative alterations. Nutrition 2011; 27(6): 693-9.[http://dx.doi.org/10.1016/j.nut.2010.06.009] [PMID: 20869209]
[13]
Shivendra. D, ChoudhryAA Oxidative stress in urinary tract infection. IJSR 2015; 1: 2324-5.
[14]
Kirschbaum B. Total urine antioxidant capacity. Clin Chim Acta 2001; 305(1-2): 167-73.[http://dx.doi.org/10.1016/S0009-8981(01)00381-3] [PMID: 11249935]
[15]
Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004; 1033: 30-41.[http://dx.doi.org/10.1196/annals.1320.003] [PMID: 15591001]
[16]
Gülçin I. Antioxidant and antiradical activities of L-carnitine. Life Sci 2006; 78(8): 803-11.[http://dx.doi.org/10.1016/j.lfs.2005.05.103] [PMID: 16253281]
[17]
Ramadan E, Salama M. NeveenT Ahmed A. Evaluation of serum l-carnitine level in children with acute bronchial asthma. Egypt J Chest Dis Tuberc 2014; 63: 541-6.[http://dx.doi.org/10.1016/j.ejcdt.2014.03.001]
[18]
Törel Ergür A, Tanzer F, Cetinkaya O. TörelErgür A. Serum free carnitine levels in children with recurrent pulmonary infections. Acta Paediatr Jpn 1997; 39(4): 406-8.[http://dx.doi.org/10.1111/j.1442-200X.1997.tb03606.x] [PMID: 9316280]
[19]
Gheissari A, Aslani N, Eshraghi A, et al. Preventive Effect of L-Carnitine on Scar Formation During Acute Pyelonephritis: A Randomized Placebo-Controlled Trial. Am J Ther 2020; 27(3): e229-34.[http://dx.doi.org/10.1097/MJT.0000000000000875] [PMID: 30418227]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2021
Published on: 04 November, 2020
Page: [212 - 215]
Pages: 4
DOI: 10.2174/1574887115666201104154227
Price: $65

Article Metrics

PDF: 45
HTML: 1